Crystalline Mitomycin-C
Welcome to Dwaey, specifically on Crystalline Mitomycin-C page.
This medicine contains important and useful components, as it consists of
Crystalline Mitomycin-C is available in the market in concentration.
Generic Name of Crystalline Mitomycin-C - Learn More
Crystalline Mitomycin-C
Crystalline Mitomycin-C Precaution - What You Need to Know
Before initiating Crystalline Mitomycin-C, patients must consult their healthcare provider due to its potent cytotoxic effects and potential for severe side effects. Key precautions include:
- Bone Marrow Suppression: Crystalline Mitomycin-C can cause significant bone marrow suppression, leading to decreased white blood cell, red blood cell, and platelet counts. Regular blood tests are necessary to monitor blood cell levels, particularly during extended therapy.
- Renal Function: Mitomycin-C is excreted primarily by the kidneys, and patients with renal impairment may experience an increased risk of toxicity. Kidney function should be monitored closely, and dosage adjustments may be required.
- Liver Dysfunction: The drug may exacerbate liver dysfunction in patients with pre-existing liver disease. Liver enzymes should be monitored before and during treatment.
- Pregnancy and Breastfeeding: Mitomycin-C is a Category D drug during pregnancy, meaning it can harm the fetus. It should not be used during pregnancy unless absolutely necessary. It is also contraindicated in breastfeeding, as it can pass into breast milk.
- Use in Combination with Other Chemotherapy Agents: When used in combination with other chemotherapy drugs, Mitomycin-C may increase the risk of toxicities, including gastrointestinal, hematological, and renal toxicities. The healthcare provider should closely monitor patients undergoing polychemotherapy regimens.
Crystalline Mitomycin-C Indication - Uses and Benefits
Crystalline Mitomycin-C is primarily used as a chemotherapeutic agent to treat various cancers. Its indications include:
- Bladder Cancer: Mitomycin-C is commonly used for the treatment of superficial bladder cancer and as an adjuvant therapy following transurethral resection of the tumor.
- Gastrointestinal Cancer: It is utilized in the treatment of gastric cancer, colorectal cancer, and esophageal cancer, often in combination with other chemotherapy drugs.
- Breast Cancer: Mitomycin-C is occasionally used in combination with other chemotherapeutic agents for the treatment of breast cancer.
- Pancreatic Cancer: This drug can be used as part of a combination regimen for treating pancreatic adenocarcinoma.
- Non-Small Cell Lung Cancer: It is sometimes employed as part of a combination therapy for treating NSCLC.
- Topical Use in Ocular Surgery: Mitomycin-C may be used topically during ocular surgeries, such as glaucoma filtration surgery, to prevent scarring and improve surgical outcomes.
Crystalline Mitomycin-C Contraindications - Important Warnings
Crystalline Mitomycin-C is contraindicated in several conditions to ensure patient safety:
- Hypersensitivity: Patients with a known hypersensitivity (allergy) to Mitomycin-C or any of its components should not receive the drug due to the risk of severe allergic reactions.
- Severe Bone Marrow Suppression: It is contraindicated in patients with pre-existing severe bone marrow suppression, as the drug exacerbates this condition.
- Severe Renal Impairment: Mitomycin-C should be avoided in patients with severe renal dysfunction (e.g., CrCl < 30 mL/min) due to its renal toxicity.
- Pregnancy: Mitomycin-C is classified as a Category D drug during pregnancy, meaning it can cause fetal harm. It should not be used during pregnancy unless the potential benefit justifies the potential risk to the fetus.
- Severe Liver Dysfunction: Patients with severe liver disease should not receive Mitomycin-C because it may exacerbate liver dysfunction.
- Active Infection: The drug should be avoided in patients with active infections, particularly fungal, bacterial, or viral infections, as its use may impair immune function.
Crystalline Mitomycin-C Side Effects - What to Expect
The side effects of Crystalline Mitomycin-C can vary from mild to severe and require close monitoring:
- Common Side Effects:
- Nausea and vomiting
- Diarrhea or constipation
- Fatigue and weakness
- Hair loss (alopecia)
- Mucositis (inflammation of the mucous membranes)
- Decreased appetite
- Skin rash or pigmentation changes
- Severe Side Effects:
- Bone Marrow Suppression: This is one of the most serious side effects of Mitomycin-C, leading to anemia, thrombocytopenia (low platelet count), and leukopenia (low white blood cell count), which can increase the risk of infections and bleeding.
- Renal Toxicity: Kidney damage can occur, especially in patients with pre-existing renal conditions. This may manifest as reduced urine output, elevated creatinine levels, or other signs of renal failure.
- Pulmonary Toxicity: Pulmonary fibrosis and lung injury are rare but potentially fatal side effects. Symptoms may include shortness of breath, cough, and chest pain.
- Gastrointestinal Toxicity: Severe nausea, vomiting, and diarrhea may occur, which can lead to dehydration, electrolyte imbalances, and malnutrition.
- Hepatotoxicity: Liver damage can occur, particularly in patients with pre-existing liver conditions. Symptoms may include jaundice, elevated liver enzymes, and abdominal pain.
- Infertility: Both male and female patients may experience fertility issues as a result of chemotherapy, including damage to reproductive organs.
Patients should notify their healthcare provider immediately if they experience symptoms of severe side effects, such as fever, persistent pain, unusual bleeding or bruising, or signs of kidney dysfunction.
Crystalline Mitomycin-C Mode of Action - How It Works
Mitomycin-C is a cytotoxic chemotherapy agent that exerts its effects through the inhibition of DNA synthesis and cell division in cancer cells:
- Mechanism: Mitomycin-C is an alkylating agent. It works by undergoing a bioactivation process inside the cell, leading to the formation of highly reactive intermediates. These intermediates bind to DNA, causing cross-linking between the strands. This prevents DNA replication and transcription, ultimately leading to cell death.
- Effect on Tumors: The cytotoxicity is primarily directed at rapidly dividing cells, such as cancer cells. It disrupts the cell cycle, particularly in the S-phase (the phase of DNA synthesis), and induces apoptosis (programmed cell death).
- Selective Toxicity: Although it affects all rapidly dividing cells, the selective toxicity of Mitomycin-C for cancer cells is enhanced when used in combination with other chemotherapy agents or radiotherapy.
Crystalline Mitomycin-C Drug Interactions - What to Avoid
Crystalline Mitomycin-C has several notable drug interactions that can affect its efficacy and safety:
- Other Chemotherapy Drugs: When used with other alkylating agents, anthracyclines, or taxanes, the risk of side effects, such as bone marrow suppression, gastrointestinal toxicity, and renal damage, may be increased.
- Radiation Therapy: Co-administration of Mitomycin-C with radiotherapy can enhance the cytotoxic effect, but this combination may also increase the risk of tissue damage, particularly in the skin and gastrointestinal tract.
- Renal Toxic Drugs: Combining Mitomycin-C with nephrotoxic drugs (e.g., aminoglycosides, cisplatin, or cyclosporine) may increase the risk of renal toxicity. Renal function must be monitored when these drugs are used together.
- Anticoagulants: Mitomycin-C may interact with oral anticoagulants, leading to increased bleeding risk. Close monitoring of prothrombin time (PT) or international normalized ratio (INR) is recommended.
- Live Vaccines: Immunosuppressive chemotherapy agents like Mitomycin-C may reduce the effectiveness of live vaccines and increase the risk of infection. Patients should avoid live vaccines during therapy.
Crystalline Mitomycin-C Adult Dose - Recommended Dosage
The dosing of Crystalline Mitomycin-C in adults depends on the specific cancer being treated and whether it is used alone or in combination with other therapies:
- Bladder Cancer:
- Intravesical (bladder instillation): Typically, 40 mg is instilled directly into the bladder once every 1-2 weeks for up to 8 weeks.
- Gastrointestinal and Other Cancers:
- Intravenous: The typical dose for treating solid tumors is 8-12 mg/m² of body surface area, administered every 4-6 weeks, depending on the clinical response and toxicity.
- Dosing may vary based on the patient's clinical condition, response to treatment, and use of combination therapies.
Crystalline Mitomycin-C Child Dose - Dosage for Children
The use of Mitomycin-C in pediatric patients is less common but may be appropriate for certain cancers. Dosing is generally calculated based on body surface area:
- Bladder Cancer: For pediatric patients, Mitomycin-C is typically dosed 1-2 mg/kg as an intravesical therapy.
- Other Cancers: Dosing for other cancers will vary depending on the type of cancer and treatment regimen, but generally falls within the adult dose range, adjusted for body surface area and tolerance.
As always, the dosing of Mitomycin-C must be tailored to the specific needs of the patient, and careful monitoring of side effects and organ function is essential throughout treatment. Always consult with a healthcare provider before starting therapy to ensure safety and effectiveness.
Crystalline Mitomycin-C Renal Dose - Dosage for Kidney Conditions
Since Mitomycin-C is primarily excreted by the kidneys, dose adjustments are necessary in patients with renal impairment:
- Mild to Moderate Renal Impairment: For patients with a creatinine clearance (CrCl) of 30-60 mL/min, the dose of Mitomycin-C should be reduced by 50% to prevent accumulation and subsequent toxicity.
- Severe Renal Impairment: In patients with CrCl < 30 mL/min, Mitomycin-C should generally be avoided due to the risk of serious renal toxicity.
